H ydrocepHalus is one of the most common problems faced by neurosurgeons. Despite the application of endoscopic procedures for treatment, most adults and children with hydrocephalus will require the implantation of a permanent CSF diversion device. Shunts have been used since the 1950s but continue to be plagued with complications, including infection. The rate of infection generally ranges from 5% to 15% but can be much higher in certain patient subgroups, such as neonates with posthemorrhagic hydrocephalus. 15, 17, 21, 32, 42, 56 Shunt infection comes with obvious undesirable burdens to the patient, family, neurosurgeon, other health care providers, and the health care system, with both shortand long-term consequences. Infection often causes shunt Object. Infection is a serious and costly complication of CSF shunt implantation. Antibiotic-impregnated shunts (AISs) were introduced almost 10 years ago, but reports on their ability to decrease the infection rate have been mixed. The authors conducted a meta-analysis assessing the extent to which AISs reduce the rate of shunt infection compared with standard shunts (SSs). They also examined cost savings to determine the degree to which AISs could decrease infection-related hospital expenses.
malfunction, placing the patient at risk for the potential consequences. It can also lead to scarring and loculation of the ventricles, making the patient's hydrocephalus more complex, and may result in a lower IQ, an increased risk of seizures, and psychomotor retardation. 13, 36, 44, 69, 71 Furthermore, the purported cost of treating a shunt infection is upward of $50,000 in the US, making it one of the most costly implant-related infections. 18 As such, the prevention of shunt infection should be paramount. A shunt-related infection, by definition, is any infection associated with the implantation of a shunt, with the most serious in terms of potential morbidity and mortality being infected CSF or ventriculitis. A wide range of practices has been designed to prevent shunt infection, 30 and rigid adherence to a shunt surgery protocol has repeatedly been shown to decrease shunt infection rates. 14, 40, 41, 49, 55 The most common pathogens in shunt infections are gram-positive skin organisms acquired at the time of surgery, namely Staphylococcus epidermidis and S. aureus. Although antibiotic-impregnated silastic catheters were first introduced by Roger Bayston in 1977 and then were considered more specifically with shunts in 1989, 10 these devices did not become available for clinical use until about 10 years ago. The first, and still the only available, AIS was introduced in 2002. This AIS is impregnated with 0.054% rifampin and 0.15% clindamycin (Bactiseal, Codman, Johnson & Johnson). Although it does not reduce bacterial adherence, this combination of antibiotics kills bacteria and thus prevents colonization by the most common pathogens for up to 56 days in in vitro studies and up to 127 days in vivo. 9, 11, 46 The AIS has also been shown to be nonepileptogenic. 1 Since the introduction of the AIS, there have been a number of studies evaluating its effectiveness compared with SSs. Some investigators have shown that the use of AISs decreases the risk of shunt infection, but others have not. Our primary objective in the present study was to combine data from existing studies to maximize their power to determine whether a difference in shunt infection rates truly exists, that is, to minimize the chance of incorrectly concluding that there is no difference. Secondly, in this era of escalating health care expenditures, we believe it is important to present cost-savings data on AIS systems. We hope to clarify whether AISs can lower the infection risk and identify the added costs and potential savings, so that surgeons can best determine whether it is clinically and economically indicated to use the AIS at their institutions.
Methods

Search Strategy
Our systematic search strategy involved an electronic database search, a manual search of journals, examination of bibliographies of relevant articles, and consultation with the senior author (F.A.B.). We electronically searched MEDLINE (via NLM Gateway), PubMed, The Cochrane Library, Web of Knowledge, and Scopus to find English-language articles published from January 2000 to April 2011 while using the following terms in various combinations: "antibiotic-impregnated," "shunt," "catheter," "system," "infection," and "hydrocephalus." Articles were also searched using the "Related Articles" function on PubMed and by reviewing the references from articles identified in the aforementioned searches. We excluded so-called grey literature, such as conference proceedings, abstracts, and trial registries.
Inclusion Criteria, Data Extraction, End Points, and Definitions
The goal of the search strategy was to identify studies published in the English language that satisfied the following criteria: 1) the study had a group of patients (adult or pediatric) that was treated with an AIS (treatment group); 2) the study had a group of patients (adult or pediatric) that was treated with an SS (control group); 3) the chosen implanted shunt system represented the only intentional treatment difference between the 2 patient groups (that is, no other changes were indicated, such as a difference in surgical technique); and 4) the minimum data included the total number of procedures performed in each group (treatment and control) and the number of shunt infections. Studies were excluded if they contained data that had been previously published (duplicated data) or if the authors used an AIS system other than the Codman Bactiseal system. Two individuals (P.K. and B.T.R.) independently screened all potential articles and extracted data from eligible articles. For all studies, we collected the following data (for the AIS and SS groups) if available, in addition to what was stated in the inclusion criteria above: study type, study population, number of patients, number of patients younger than 1 year, number of shunt operations, average age, age range, initial or revision operation, recent shunt infection (usually within the last 6 months), type of hydrocephalus (communicating, obstructive, or unclear), and cause of hydrocephalus (congenital; posthemorrhagic, including postsubarachnoid hemorrhage and germinal matrix hemorrhage of prematurity; spina bifida; normal pressure hydrocephalus; posttraumatic; tumor; and postmeningitic).
Although the primary outcome for the purpose of this meta-analysis was shunt infection, its definition was, of course, determined by the authors of the studies that met our entry criteria. In general, a CSF shunt/catheterrelated infection was present if a patient had signs and symptoms of shunt malfunction or infection with an organism cultured from the CSF, shunt apparatus, purulence from the shunt wound(s), or abdominal fluid/pseudocyst. Some investigators also included patients in whom the clinical suspicion was very high (for example, raised CSF white blood cell count, clinical improvement after shunt removal, and treatment with antibiotic therapy) but positive CSF cultures were lacking. 33, 38 The shunt infection rate was calculated per procedure, rather than per patient, for 2 reasons. First, we judged that it was more clinically relevant because some patients undergo multiple shunt revisions, and second, in some studies, the total number of patients was not provided.
Each study that met our inclusion criteria was carefully reviewed independently, and the authors' conclusions were verified based on the data provided. Disagreements in study selection and data abstraction were resolved through discussion. The quality of the evidence provided in each study was then graded I-IV (Table 1) . 4 We used 2 classification systems to grade the strength of our recommendations on the use of AISs based on the results of our meta-analysis (Tables 2 and 3) . 58, 68 The Meta-Analysis
For each study, we identified the number of infections resulting from SSs and AISs and then computed the risk of an infection with the AIS relative to the SS, yielding an RR. An RR < 1 indicates protection against infection with the AIS. The overall risk ratio was computed using the method of DerSimonian and Laird. 20 We conducted a random effects meta-analysis of the selected studies. A random effects model-as opposed to a fixed effects model-does not assume that the measure of association (that is, the RR) is uniform across strata (that is, among studies) and consequently yields a more conservative estimate of the effect. We assessed heterogeneity using the chi-square test of heterogeneity and the I 2 statistic, where the former returns a chi-square distributed test statistic and corresponding p value and the latter returns a value bound between 0% and 100%, with higher values denoting increasing heterogeneity. We regarded a chi-square test of heterogeneity p value less than α = 0.10 and an I 2 value in the range of 30%-60% as suggestive of moderate heterogeneity. 16, 19 To examine the source of heterogeneity, we categorized the studies based on their institutional status (single vs multiinstitutional) and analyzed each group separately (sensitivity analysis). We hypothesized that this stratification would account for some of the observed heterogeneity. We initially excluded studies that presented pooled data from multiple institutions because we judged that single-institution data were "cleaner," that is, any difference in the infection rate between the treatment and control groups was more likely a result of the intervention (switching from an SS to an AIS) than a result of any one or more of the large number of variables that could positively or negatively affect the primary outcome (that is, confounders). Nonetheless, we reasoned that the data from the multiinstitutional studies were important enough to be included, although we elected to analyze them separately (see Results). We also assessed the presence of publication bias via a funnel plot. 22, 66, 67 All statistical analysis was conducted using Stata/SE 11.2 software.
The Cost-Benefit Analysis
For each study in which a statistically significant reduced infection rate was demonstrated for the AIS, we calculated an ARR and RRR. The number of AISs that would need to be implanted to prevent 1 shunt infection, or the number needed to treat (NNT), was calculated for each study as the inverse of the ARR. We then calculated the cost of preventing 1 shunt infection as the NNT multiplied by the additional cost of an AIS system, which is approximately $400. Next, assuming a cost of $50,000 to a treat shunt infection, we calculated the savings per NNT and the savings per annum, assuming that the institution performs 200 shunt operations per year.
Results
The initial search strategy identified 22 studies, but several articles were disqualified from analysis. Izci et al. 34 used a silver-impregnated polyurethane ventricular catheter that has not been evaluated by others and is not commercially available in the US. Two groups of authors presented similar data in multiple publications; we chose the publication that provided the most detailed data. The group from Johns Hopkins University has published at least 8 studies that detail their experience with AIS over different but overlapping time periods. 8, 26, 27, 45, [59] [60] [61] [62] Two publications were selected for this analysis because they had a large number of patients over extended time periods, with each study focusing on pediatric or adult patients only. 26, 45 Likewise, Eymann and colleagues 24,25 had 2 publications with shared data, and the one used for this meta-analysis was selected because it included both adult and pediatric patients and also had a cost-benefit analysis. Thus, 14 studies met our inclusion criteria. 2, 7, 24, 26, 29, 31, 33, 37, 38, 45, 47, 53, 54, 65 Note, however, that the study by Eymann et al. 24 had separate data for adult and pediatric patients, and thus each population was analyzed and listed separately. prospective matched group cohort study in representative population w/ masked outcome assessment that meets requirements listed above OR a randomized controlled trial in representative population that lacks 1 of the criterion listed above III all other controlled trials including well-defined natural history controls or patients serving as own controls in representative population in which outcome assessment is independently assessed or independently derived by objective outcome measures (that is, an outcome measure that is unlikely to be affected by an observer's (patient, treating physician, or investigator) expectation or bias (for example, blood tests or administrative outcome data) IV evidence from uncontrolled studies, case series, case reports, or expert opinion
Characteristics of Eligible Studies
There were 2 prospective studies (1 controlled cohort and 1 randomized), 2 ambidirectional cohort studies (data collected both retro-and prospectively), and 10 retrospective cohort studies (Table 4) . Eleven studies involved patients from a single institution, and 3 studies included data from multiple institutions. Two of these multiinstitutional studies were from the United Kingdom. Although the study by Richards et al. 53 used data from the UK Shunt Registry in which "all major neurosurgery centers" in the British Isles contribute, we could not confidently assume that the data from the 3 neurosurgery units presented in the Kandasamy et al. 38 study were also used in the Richards et al. study. Furthermore, Kandasamy et al. only reported on pediatric patients. Therefore, it was decided to include both studies. Seven studies contained both adult and pediatric patients, 5 had just pediatric patients, and 2 had only adults. All studies except 1 were graded as having Level III data. The study by Govender et al. 29 was a prospective randomized trial but was downgraded to Level II data quality because of serious methodological and data interpretation flaws, including the lack of clearly defined primary outcome and demographic data for the treatment and control groups (see Discussion). The demographic data for patients in the SS and AIS groups within each study are detailed in Tables 5 and 6 .
Tests for Evidence of Publication Bias
There is a trend toward a modest publication bias in our analysis, although this bias was not statistically significant (p = 0.103). The absence of studies in the lower 
Meta-Analysis: Shunt Infection and Sensitivity Analysis
Among the 14 studies, 7 showed AISs to be protective in preventing a shunt malfunction and 7 documented no statistical benefit (Table 7) . There were 5582 procedures involving a standard catheter system and 390 infections, yielding a pooled infection rate of 7.0%. In the population receiving AISs, there were 120 infections among 3467 shunt operations, for an overall infection rate of 3.5%.
When analyzing only the single-institution studies (12 study populations), the overall RR was 0.38 (95% CI 0.25-0.58, p < 0.001; Fig. 2) . In other words, a shunt infection was 2.63 times more likely when using an SS than an AIS. If all studies were included (15 studies, including both data sets from Eymann et al. 24 ), then the overall RR was 0.46 (95% CI 0.33-0.63, p < 0.001), making shunt infection 2.18 times more likely with an SS system. There was evidence of some heterogeneity when all of the studies were analyzed together (Q = 21.33, df = 14, p = 0.093), but when we examined the studies according to their institutional status, the heterogeneity was reduced to statistically nonsignificant levels (p > 0.10 for both single-and multiinstitutional studies). The stratification of our analysis-a sensitivity analysis according to study institutional status-indicated that the observed heterogeneity was partially explained by institutional status. Furthermore, the I 2 statistic decreased from 34.4% for all studies to 29.0% for single-institution studies, suggesting that the institutional status accounted for some of the overall heterogeneity, with the remaining heterogeneity attributable to differences between the single-institution studies. Our recommendation on the use of AISs is strong evidence with low-to moderate-quality evidence based on the GRADE system/ATS guidelines and Class IIa evidence based on the ACC/AHA guidelines.
Cost-Savings Analysis
As the difference in infection rates between patients who had an SS and those who had an AIS increases, the NNT to prevent 1 shunt infection consequently decreases (Table 8) . For example, the study by Gutiérrez-González et al. 31 showed a decrease in the infection rate from 17% to 2.8%, yielding an NNT of 7. A lower NNT translates into a lower additional cost for switching to the AIS (assuming an additional hospital cost of $400 per AIS kit). Assuming a cost of $50,000 to treat a shunt infection, the cost savings per shunt infection prevented for the various studies is shown in Table 8 . The estimated annual savings, assuming 200 shunt operations performed, ranges from just under $90,000 to well over $1.3 million.
Discussion
Literature Review
Of the 14 studies that satisfied our inclusion and exclusion criteria, 7 revealed AISs to be statistically protective, 24, 26, 31, 38, 45, 47 ,53 whereas 7 did not. 2, 7, 29, 33, 37, 54, 65 Among the studies with negative statistical findings, one 2 had such a small number of patients (18 patients, 6 with AISs) that no conclusion could be made, although the authors believed that the "AIS could be effective." The authors of 2 studies 29, 33 made somewhat misleading comments in their respective abstracts that required us to classify them as finding no benefit with the AIS. Hayhurst et al. 33 stated that "AIS catheters can reduce the number of shunt infections" and "had a significant impact on the neonatal hydrocephalic population," when in fact their results showed no difference in the shunt infection rate overall and within any subgroup, including neonates. Proponents of AISs have given much credence to the prospective randomized trial by Govender et al. 29 These authors provided a definition of shunt infection, even differentiating between an "internal" and an "external" infection, and described their inclusion and exclusion criteria, surgical † Less than or equal to 6 months of age. ‡ Data are from a single paper, but the authors analyzed pediatric and adult patients separately, and so the data are listed separately. procedure, sample size calculation, and follow-up protocol. Nevertheless, their study suffered from a number of critical flaws. The investigators failed to provide a clear definition of their primary end point; they did not discuss the method of randomization and whether any known shunt infection risk factors, such as prematurity, would be controlled for in the randomization process or data analysis; and they did not provide the demographic makeup of the treatment or control groups to demonstrate whether they were balanced. They focused their conclusion on their finding of a decreased shunt infection rate in the first 2 months in the AIS group, but the overall shunt infection rate, which we believe is more clinically relevant, was not statistically different between the AIS (5%) and SS (13.3%) groups. Furthermore, this study was conducted in a region of South Africa where the prevalence of HIV is the highest, and the patients, as stated by the authors, often have an extremely poor socioeconomic status, are severely malnourished, and have poor immunocompetency. These factors, therefore, limit the external validity, or generalizability, of this study as compared with other studies in the literature from more socioeconomically advanced countries.
There was a mild publication bias in the articles used in the meta-analysis, as depicted by the lack of uniform distribution within the inverted V of the funnel plot (Fig. 1) , which suggests that small, negative studies have not been published in the literature. Furthermore, as mentioned in the Results, authors from Johns Hopkins University have published multiple articles with duplicate data, all of which have revealed a positive effect with AISs. 8, 26, 27, 45, [59] [60] [61] [62] This duplication has the effect of flooding the literature with results that could have been coalesced into fewer studies. To control for this effect, we selected only those studies that had distinct data-1 study that had adult patients and 1 study that contained only pediatric patients. Even more concerning is the fact that 2 authors who are associated with all of the studies are self-admitted paid consultants for Codman, which could raise questions regarding the unbiased nature of the studies and results.
Meta-Analysis and Limitations
Our meta-analysis showed AISs to be protective against shunt infection. The pooled infection rate de- creased from 7.0% in the patients in the SS group to 3.5% in those in the AIS group-ARR and RRR of 3.5% and 50%, respectively. Regardless of whether all studies were included or only those from a single institution, the odds of a shunt infection developing was more than 2 times greater in patients with an SS than in those who received an AIS.
Since a meta-analysis is a summation of trials, it is only as good as the trials that are combined within it. Although the trials used in this meta-analysis shared certain core components, as defined by our inclusion and exclusion criteria, and all had Class III data, with the exception of 1 study with Class II data, there was a considerable degree of heterogeneity among them. For example, some studies included only adult patients, others had only children, and still others included both. Surgical technique is obviously a factor that cannot be controlled for in such an analysis and, as discussed previously, may be somewhat more "standardized" in a study from a single institution than in a multiinstitutional study. Even the definition of a shunt infection was not identical from study to study. The availability of composition data for the control and treatment groups within each of the studies varied considerably, even for seemingly basic data such as sex and age (Tables 5 and 6 ). Some studies gave little to no compositional data for the treatment or control groups. 7, 47, 54 The most important implication regarding group composition * NNT × $400. † $50,000 − (NNT × $400). ‡ (200/NNT) × [$50,000 − (NNT × $400)]. § Data are from a single paper, but the authors analyzed pediatric and adult patients separately, and so these data are listed separately.
is whether collectively the treatment and control groups are balanced for some of the known prognostic factors (that is, confounders) for shunt infection.
Various primarily nonmodifiable preoperative patient characteristics are thought to be risk factors for shunt infection. Newborns (younger than 6-12 months of age) and premature infants in particular (< 40 weeks gestation), with their immature immune systems, thin skin, and high bacterial skin flora, have frequently been shown in the literature to be high-risk groups, with infection rates of 10%-15% or higher. 3, 23, 28, 43, 50, 63, 70 A few reports have not shown age to be a risk factor. 42, 65 Simon et al. 63 also identified female sex, African-American race, public insurance, cause of intraventricular hemorrhage, and respiratory complex chronic condition as risk factors. Kestle et al. 39 found an alarmingly high overall reinfection rate of 26% in patients who were treated for a recent CSF shunt infection and 29% in those infected with S. epidermidis. Ritz et al. 54 "assumed" a number of shunt infection risk factors as part of their data analysis, including age (< 1 and > 80 years), premature birth, EVD, former shunt infection, former systemic infection, disturbance of consciousness, and former radiation or chemotherapy. Prusseit et al. 51 listed a number of "confirmed" risk factors, which included among others low gestational age and preterm birth, young age at shunt placement, and cause of hydrocephalus (increased risk after intraventricular hemorrhage, infectious etiology, or children with malignant disease, chemotherapy-associated immunosuppression, or long-term application of steroids). High-risk subgroups as defined by Parker et al. 45 were characterized by prematurity (< 35 weeks gestational age), placement of shunts immediately after meningitis, conversion of an EVD to a shunt, and shunt replacement due to nosocomial infection in patients requiring prolonged hospital stays (> 1 month). Pattavilakom et al. 47 listed similar risk factors such as cause of hydrocephalus, previous revisions, extended hospital stay, positive CSF cultures prior to implantation, and the preoperative occurrence of CSF leakage or the use of an EVD.
What this demonstrates is that there are undoubtedly a number of known and unknown preoperative risk factors or confounders for shunt infection, with varying degrees of agreement among neurosurgeons collectively. It is impossible based on the studies that qualified for our meta-analysis to know whether the SS and AIS groups were balanced with respect to even the more commonly cited risk factors simply because such data were not available in all studies. Our hope is that with so many patients and procedures in each treatment group (5582 and 3467 procedures in the SS and AIS groups, respectively), the influence that any differences between the groups as regards known and unknown confounders would be lessened, and thus the statistically significant and substantial reduction in the infection rate that we demonstrated is a true finding and not a false positive or a Type I error.
Steps may be taken at the design stage or in the analysis stage of a clinical study to reduce the impact of disproportionately distributed confounders. Matching groups on certain key confounders, as done in the study by Richards et al., 53 can eliminate the impact of only those confounders that were matched, but matching on multiple confounders in a large cohort trial can be economically and logistically impracticable. Although some authors have called for a prospective, blinded, randomized controlled trial, 37 such an analysis would require, as correctly stated by Richards et al., 53 very large patient numbers, which would necessitate multicenter cooperation, the establishment of a standard protocol, and considerable funding. For example, if we assumed that the shunt infection rates in our meta-analysis were true, with a b of 20% and an α of 5%, more than 500 patients would be needed in each group. More importantly, it may be difficult to recruit centers into such a trial because, anecdotally, some neurosurgeons and centers have developed a strong bias toward using the AIS (that is, lack of clinical equipoise). It is easy to understand why. For the neurosurgeon, converting to the AIS requires no change in surgical technique or added surgical time and may reduce the risk of what is arguably one of the most adverse complications of shunt surgery. Furthermore, there have been no reported deleterious consequences of implanting an AIS. Although there has been some concern that AIS systems may "mask" or delay shunt infections or even increase the rate or virulence of such an infection, Sciubba et al. 60 showed that AISs did not increase the incidence of late CSF shunt infection. There have been no reports of postsurgical hypersensitivity, and Abed et al. 1 demonstrated that AISs are nonepileptogenic. Nonetheless, the Hydrocephalus Clinical Research Network developed and implemented a standardized shunt surgery protocol that excluded the use of AISs in 4 centers with 21 neurosurgeons. 41 In the absence of a well-designed prospective cohort trial or randomized trial, we believe that our meta-analysis provides the best evidence-based appraisal of the current literature. Using the ATS/GRADE system, we strongly recommend the use of AISs based on low-to moderatequality evidence (Class II and III data). Similarly, we give our findings a Grade IIb on the ACC/AHA scale, which indicates that, although there is some conflicting evidence, the weight of the evidence favors AIS use.
Cost Analysis and Limitations
The implantation of shunts is a very common procedure and thus uses tremendous monetary resources. Each year, more than $2 billion dollars are spent treating pediatric hydrocephalus, with an estimated cost of $36,000-$40,000 per admission. 48, 64 The cost to treat a shunt infection may be upward of $50,000 or more. 18 Therefore, the impact of a measure to decrease the risk of shunt infection can translate into substantial health care savings.
The greater the risk reduction with a conversion to AISs, the lower the number of AIS implants needed to prevent 1 infection and thus the less additional cost to prevent 1 shunt infection, assuming the commonly quoted additional cost of $400 for an AIS system (at the primary author's hospital [P.K.], the difference is $412.48). With a lower NNT and thus lower additional expenditure to prevent 1 shunt infection, the cost savings per NNT (assuming a cost of $50,000 to treat a shunt infection) and cost savings per annum (assuming 200 shunt operations/year) increases accordingly. The savings per annum in trials that showed a benefit with AIS systems ranged from just less than $90,000 to over $1.3 million (Table 8) .
The cost savings are dependent on several factors and assumptions. The biggest factor is the decrease in the shunt infection rate with a change to the AIS (ARR). In some institutions, the shunt infection rates are so low that converting to AISs would not be financially worthwhile. Choux et al.
14 reported a per-procedure rate of 0.17% after the introduction of a strict protocol for shunt surgery. With the addition of intrathecal vancomycin and gentamycin at the time of surgery, Ragel et al. 52 saw their infection rate fall to 0.4%. Pirotte et al. 49 reported the lowest infection rate in the literature, 0%, in a consecutive series of 100 patients undergoing 115 surgeries with the implementation of their own perioperative protocol. Thus, if an institution's shunt infection rate is already well below 5% with the use of standard catheters, converting to AISs may not be cost effective or may best be limited to patients at greatest risk for shunt infection (for example, premature infants).
A significant assumption in our analysis was the cost of treating a shunt infection. Darouiche 18 estimated the medical and surgical cost of treating a shunt infection to be $50,000. Attenello et al. 8 recently reported the average hospital cost per shunt infection for AIS and SS catheters as $46,640 and $49,397, respectively. At the primary author's institution (P.K.), the average cost in 2010 was $51,741. The cost to treat a shunt infection is dependent on 2 primary variables: how the shunt infection is treated and the health care system under which the patient is treated. There is no uniform method or duration of treatment for shunt infection, 6 ,39 but one of the more common procedures involves the removal of all hardware at the time of diagnosis, placement of an EVD for a period of several days or weeks while the patient is treated with intravenous (and possibly intraventricular) antibiotics until the infection clears, and reimplantation of a new shunt. 35, 39, 57 Other authors have reported successful outcomes with externalization of the shunt and treatment with systemic and intraventricular antibiotics followed by implantation of a new shunt 5 or in situ treatment with systemic and intraventricular antibiotics in patients with coagulase-negative staphylococci without externalization or replacement of the hardware. 12 As an example of the difference in hospital costs between markedly different health care systems, Eymann et al. 24 reported a much lower average cost of $17,300 and $13,000 for children and adults, respectively, under the socialized government-run German health care system. Even with a much lower cost in treating a shunt infection, they still saved approximately $50,000 with nearly 200 shunt operations. We chose $50,000 as the total cost because we believe it most likely reflects the cost of a shunt infection in the US. Annual cost savings were calculated based on 200 shunt operations being performed during that year, a number we thought was reasonable for a typical high-volume children's hospital where the impact of savings would be the greatest.
Conclusions
Shunt infections can have long-term consequences to the patient and impose significant burdens on the family, neurosurgeon, and health care system. The prevention of shunt infection is therefore critically important. The AIS system has been a welcome addition to the treatment of patients with hydrocephalus, but its effectiveness remains unclear. While recognizing the variable quality of existing literature, the lack of a uniform definition of "shunt infection," and a possible publication bias, we have nonetheless shown in our meta-analysis the protective effect of AISs. The infection rate decreased from 7.0% with SSs to 3.5% with AISs. When all 14 studies were included in our analysis, the risk of developing a shunt infection with an SS was 2.18 times greater than that with an AIS. The protective effect of the AIS translated into a significant per annum cost savings, ranging from $90,000 to over $1.3 million. Economically, the decision to convert to an AIS system must be institution-based and is dependent on the baseline shunt infection rate, the estimated change with conversion to an AIS, the average hospital costs for the treatment of a shunt infection, and the number of shunt operations performed at the institution. Unless an institution's shunt infection rate is already well below 5%, we believe that an AIS should strongly be considered in all patients, especially in those who have the highest risk of shunt infection.
